TR200101644T2 - TNF-ALFA önleyicileri olarak siklik hidrazin türevleri. - Google Patents
TNF-ALFA önleyicileri olarak siklik hidrazin türevleri.Info
- Publication number
- TR200101644T2 TR200101644T2 TR2001/01644T TR200101644T TR200101644T2 TR 200101644 T2 TR200101644 T2 TR 200101644T2 TR 2001/01644 T TR2001/01644 T TR 2001/01644T TR 200101644 T TR200101644 T TR 200101644T TR 200101644 T2 TR200101644 T2 TR 200101644T2
- Authority
- TR
- Turkey
- Prior art keywords
- tnf
- hydrazine derivatives
- cyclic hydrazine
- formula
- alfa inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/34—Ethylene-urea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
- C07D251/34—Cyanuric or isocyanuric esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formül (I)'in hidrazin türevleri ve hücrelerden tümör nekroz faktörü alfanin (TNF-alfa) birakilmasini önleyen farmasötik olarak uygun olan tuzlari. Bunlar özellikle iltihaplanmali ve otoimmün hastaliklarin, osteoartrit'in, solunumla ilgili hastaliklarin, tümörlerin, kaseksi'nin, kalpdamar sistemi hastaliklarinin, yüksek atesin, kanamalarin ve septisemi'nin tedavisinde ilaç olarak kullanilabilmektedirler. (FORMÜL VAR)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9827408.7A GB9827408D0 (en) | 1998-12-11 | 1998-12-11 | Hydrazine derivatives |
GBGB9925211.6A GB9925211D0 (en) | 1999-10-25 | 1999-10-25 | Hydrazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200101644T2 true TR200101644T2 (tr) | 2001-11-21 |
Family
ID=26314825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01644T TR200101644T2 (tr) | 1998-12-11 | 1999-12-02 | TNF-ALFA önleyicileri olarak siklik hidrazin türevleri. |
Country Status (14)
Country | Link |
---|---|
US (1) | US6281363B1 (tr) |
EP (1) | EP1137640B1 (tr) |
JP (1) | JP3913983B2 (tr) |
KR (1) | KR100442223B1 (tr) |
CN (1) | CN1132819C (tr) |
AT (1) | ATE305003T1 (tr) |
AU (1) | AU765729B2 (tr) |
BR (1) | BR9916005A (tr) |
CA (1) | CA2353924A1 (tr) |
DE (1) | DE69927403T2 (tr) |
DK (1) | DK1137640T3 (tr) |
ES (1) | ES2249055T3 (tr) |
TR (1) | TR200101644T2 (tr) |
WO (1) | WO2000035885A1 (tr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2393802C (en) * | 2000-01-24 | 2011-04-19 | Warner-Lambert Company | 3-aminoquinazolin-2,4-dione antibacterial agents |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
EP2039695A4 (en) | 2006-07-11 | 2010-09-15 | Takeda Pharmaceutical | BICYCLIC HETEROCYLIC COMPOUND AND ITS USE |
DK2433940T3 (en) | 2009-04-28 | 2015-01-12 | Chugai Pharmaceutical Co Ltd | Spiroimidazolonderivat |
NO2930176T3 (tr) | 2012-12-10 | 2018-07-07 | ||
BR112016003511B8 (pt) | 2014-06-09 | 2023-10-03 | Chugai Pharmaceutical Co Ltd | Composição farmacêutica que contém derivados de hidantoína e uso dos mesmos |
CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2058797A1 (en) | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
US5399589A (en) | 1992-12-17 | 1995-03-21 | Basf Aktiengesellschaft | Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides |
GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
WO1999040063A1 (fr) | 1998-02-06 | 1999-08-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Nouveaux derives de l'acide hydroxamique de type azapeptide |
US6239151B1 (en) | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
-
1999
- 1999-12-02 TR TR2001/01644T patent/TR200101644T2/tr unknown
- 1999-12-02 CA CA002353924A patent/CA2353924A1/en not_active Abandoned
- 1999-12-02 DK DK99965432T patent/DK1137640T3/da active
- 1999-12-02 BR BR9916005-6A patent/BR9916005A/pt not_active Application Discontinuation
- 1999-12-02 DE DE69927403T patent/DE69927403T2/de not_active Expired - Fee Related
- 1999-12-02 KR KR10-2001-7007253A patent/KR100442223B1/ko not_active IP Right Cessation
- 1999-12-02 JP JP2000588147A patent/JP3913983B2/ja not_active Expired - Fee Related
- 1999-12-02 WO PCT/EP1999/009423 patent/WO2000035885A1/en active IP Right Grant
- 1999-12-02 EP EP99965432A patent/EP1137640B1/en not_active Expired - Lifetime
- 1999-12-02 AT AT99965432T patent/ATE305003T1/de not_active IP Right Cessation
- 1999-12-02 CN CN998143235A patent/CN1132819C/zh not_active Expired - Fee Related
- 1999-12-02 ES ES99965432T patent/ES2249055T3/es not_active Expired - Lifetime
- 1999-12-02 AU AU20950/00A patent/AU765729B2/en not_active Ceased
- 1999-12-09 US US09/457,798 patent/US6281363B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3913983B2 (ja) | 2007-05-09 |
WO2000035885A1 (en) | 2000-06-22 |
CA2353924A1 (en) | 2000-06-22 |
DK1137640T3 (da) | 2006-02-06 |
ES2249055T3 (es) | 2006-03-16 |
CN1132819C (zh) | 2003-12-31 |
AU2095000A (en) | 2000-07-03 |
EP1137640B1 (en) | 2005-09-21 |
CN1330640A (zh) | 2002-01-09 |
EP1137640A1 (en) | 2001-10-04 |
KR20010086096A (ko) | 2001-09-07 |
US6281363B1 (en) | 2001-08-28 |
JP2002532478A (ja) | 2002-10-02 |
AU765729B2 (en) | 2003-09-25 |
KR100442223B1 (ko) | 2004-07-30 |
DE69927403T2 (de) | 2006-07-06 |
BR9916005A (pt) | 2001-09-04 |
ATE305003T1 (de) | 2005-10-15 |
DE69927403D1 (de) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199903281T2 (tr) | Hidrazin türevleri. | |
TR200002980T2 (tr) | İnhibe edici etkiye sahip ikame edilmiş indolinonlar | |
TR200200160T2 (tr) | Antiinflamatuar ajanlar olarak imidazoller ve triazoller | |
UA84175C2 (ru) | Гетероциклические ингибиторы мэк и их применение | |
TR199900308T2 (tr) | Tiyenopirimidinler | |
PL375560A1 (en) | A pharmaceutical composition | |
NO20005448L (no) | Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert på patologisk celleproliferering | |
JO2293B1 (en) | Derivatives of 3-indoleil 4-phenyl-1H-birol-5.2 -Dayon as inhibitors of glycogen synthacinase-3b | |
EP2767291A3 (en) | Treatment of glycogen storage disease type II | |
ATE551988T1 (de) | Orale zusammensetzungen, ihre herstellung und verwendung | |
MY129941A (en) | Novel dihydro-isoquinoline derivatives | |
MX2007009777A (es) | Derivados de triazol. | |
EP2270042A3 (en) | KDR peptides and vaccines comprising the same | |
ES2183877T3 (es) | Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias. | |
TR200101644T2 (tr) | TNF-ALFA önleyicileri olarak siklik hidrazin türevleri. | |
BR0007589A (pt) | Inibidores da proliferação de células | |
CY1105097T1 (el) | Χρηση παραγωγων ν-φαινυλο-2-πυριμιδιναμινης στην αγωγη εναντι φλεγμονωδων ασθενειων | |
AP1408A (en) | Phenyl yanthine derivatives. | |
MXPA05010174A (es) | Derivados de indol e indolina sustituidos. | |
GB0314967D0 (en) | Piperazine derivatives | |
UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
DE50211929D1 (en) | Pyrimidinderivate | |
WO2001027080A3 (de) | In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren | |
Reed et al. | The role of diffusion processes in fertility change in developing countries: report of a workshop | |
TR200101495T2 (tr) | Hidrazin türevleri |